Pulmonary Inflammatory Response in Lethal COVID-19 Reveals Potential Therapeutic Targets and Drugs in Phases III/IV Clinical Trials

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etiological agent of the coronavirus disease 2019 (COVID-19), has led to more than 425 million cases and more than 5.9 million deaths globally (WHO, 2021). Since the World Health Organization (WHO) declared the outbreak of COVID-19 as...

Cur síos iomlán

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	López Cortés, Andrés (author)
Rannpháirtithe:	Guerrero, Santiago (author), Ortiz Prado, Esteban (author), Yumiceba, Verónica (author), Vera Guapi, Antonella (author), León Cáceres, Ángela (author), Simbaña Rivera, Katherine (author), Gómez Jaramillo, Ana María (author), Echeverría Garcés, Gabriela (author), García Cárdenas, Jennyfer M. (author), Puig San Andrés, Lourdes (author), Guevara Ramírez, Patricia (author), Cabrera Andrade, Alejandro (author), Bautista, Jhommara (author), Pérez Villa, Andy (author), Ramos Medin, María José (author), Pérez Meza, Álvaro Alexander (author), Nieto Jaramillo, Karol (author), Jácome, Andrea V. (author), Morillo, Andrea (author)
Formáid:	article
Foilsithe / Cruthaithe:	2022
Ábhair:	ulmonary inflammatory response Clinical trials, drugs Lethal COVID-19 Single nucleus RNA sequencing
Rochtain ar líne:	https://doi.org/10.3389/fphar.2022.833174 http://repositorio.ikiam.edu.ec/jspui/handle/RD_IKIAM/529
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Bí ar an gcéad duine le trácht a dhéanamh!

Pulmonary Inflammatory Response in Lethal COVID-19 Reveals Potential Therapeutic Targets and Drugs in Phases III/IV Clinical Trials

Míreanna comhchosúla